Subscribe To
NAMS / NewAmsterdam: An Underfollowed Dutch Biotech Cardiovascular Biotech
NAMS News
By Seeking Alpha
October 2, 2023
NewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakthroughs
New clinical data shows the potential of obicetrapib in treating early Alzheimer's disease in patients with the ApoE4 mutation. The Phase IIa trial de more_horizontal
By GlobeNewsWire
September 20, 2023
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or more_horizontal
By Seeking Alpha
August 19, 2023
NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023
NewAmsterdam Pharma showcased positive trajectory in Q2 2023 financial report, with over-enrollment in obicetrapib's Ph.3 BROADWAY trial indicating ro more_horizontal
By The Motley Fool
June 7, 2023
Why Shares of NewAmsterdam Pharma Were Plummeting on Wednesday
NewAmsterdam is a clinical-stage biopharmaceutical company with a lead therapy candidate that lowers cholesterol levels. The company is examining the more_horizontal
By Seeking Alpha
March 13, 2023
NewAmsterdam: An Underfollowed Dutch Biotech Cardiovascular Biotech
NewAmsterdam Pharma is a Dutch SMID cap biotech focusing on cardiovascular diseases. NewAmsterdam Pharma has a promising pipeline drug called Obicetra more_horizontal